Intermittent vs Continuous Administration of Pazopanib in Progressive Radioiodine-Refractory Thyroid Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
Eur. J. Cancer 2021 Sep 09;157(xx)153-164, C de la Fouchardière, Y Godbert, C Dalban, F Illouz, J Wassermann, C Do Cao, S Bardet, S Zerdoud, CN Chougnet, M Zalzali, D Benisvy, P Niccoli, L Digue, L Lamartina, P Schwartz, F Borson Chazot, J Gautier, D Pérol, S Leboulleux,From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.